HIV Drug Treatment Doesn’t Lower Risk of Partner Infection
For married couples in which one partner is HIV-positive and the other is HIV-negative, antiretroviral therapy (ART) does not reduce the risk of transmitting HIV to the uninfected partner, according to a study from China in the October issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes. JAIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
The new research raises questions as to the real-world effectiveness of the so-called Test-And-Treat strategy—treating HIV-positive persons with ART drugs in an effort to prevent new cases of HIV infection.
HIV Transmission Rate Is Relatively Low…
Led by Dr. Lu Wang of the Chinese Center for Disease Control & Prevention, Beijing, the study included 1,927 married couples in the city of Zhumadian, Henan Province, China.
The couples were initially “serodiscordant,” meaning that one partner had HIV while the other did not. Zhumadian has a high rate of HIV disease related to infected blood products from paid plasma donors during the early 1990s. All infected persons have free access to medical monitoring and treatment, including ART drugs.
The initially seronegative spouses were monitored regularly for “seroconversion”—that is, conversion from HIV-negative to HIV-positive. Factors associated with a higher or lower risk of HIV transmission were analyzed.
The seroconversion rate was relatively low: over a median follow-up of three years, 4.3 percent of spouses became HIV-positive. The seroconversion rate increased over time, however.
The risk of HIV transmission was higher for couples who reported more frequent sexual activity and especially for those who said they did not always use condoms. Risk was also higher for spouses who scored lower on a psychological questionnaire. The results suggest that education—particularly on the need for consistent condom use—may play an important role in preventing transmission from HIV-positive persons to their HIV-negative partners. Efforts to target psychosocial factors may also be helpful.
…But Antiretroviral Drug Treatment Doesn’t Lower the Risk
Just as important, the use of ART did not lower the risk of HIV transmission to the initially HIV-negative spouse. Risk did appear lower for couples in which the HIV-positive spouse did not switch his or her ART regimen during follow-up.
The lack of effect of ART may have important implications for HIV prevention strategies. An idea that has gained momentum in recent years is “Test and Treat” strategy—identifying as many HIV-positive people as possible and treating them with ART medications to reduce their likelihood of transmitting the infection. In theory, this strategy provides the possibility of “treating our way out of the epidemic,” according to an editorial by Dr. Myron S. Cohen of UNC Center for Infectious Diseases.
The new results from Zhumadian provide an “Important, surprising and cautionary” look at how “Test and Treat” may work, according to Dr. Cohen. In previous studies, ART significantly lowered the rate of HIV transmission in serodiscordant couples, who generally received close medical follow-up. In contrast, the Chinese study shows no reduction in HIV transmission—even though all couples had access to health care services, including ART drugs.
A formal research trial is being performed to see if ART reduces HIV transmission over five years in a large group of serodiscordant couples. Meanwhile, the new study raises a critical question: Will ART reduce HIV transmission from treated people to their sexual partners under “real life” conditions? Dr. Cohen concludes, “It would seem more than wise to try to answer this question before we fully deploy a ‘Test and Treat’ strategy, expecting to detect a benefit to the general population.”
JAIDS: Journal of Acquired Immune Deficiency Syndromes (http://www.JAIDS.com) is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic science, clinical science, and epidemiology. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
Source: Wolters Kluwer Health: Lippincott Williams & Wilkins